-
Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role
•
Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), has recently departed from the Chinese company. He will now serve as Executive Director of External Innovation at AbbVie. Dr. Chen Dong’s Background and Contributions at HengruiDr. Chen Dong studied at Wuhan…
-
Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease
•
Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin, a biosimilar version of Johnson & Johnson (J&J)’s auto-immune disease drug Stelara (ustekinumab), has been accepted for review by the National Medical Products Administration (NMPA). The Chinese firm is seeking approval for its use in…
-
J&J Innovative Medicine China Appoints New General Manager and Oncology VP
•
Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments to its leadership team. The company has appointed a new general manager and a new vice president. New General ManagerAs of March 1, 2025, Mr. Chen Jian will take on the role of head of…
-
Liaoning Chengda Biotech to See Actual Controller Change of Controlling Shareholder
•
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) announced a proposed change in the actual controller of its controlling shareholder Liaoning Chengda Co., Ltd. The actual controller will change from the State-owned Assets Supervision and Administration Commission of Liaoning Provincial Government to no actual controller. Control Change and Its ImplicationsWith…
-
Bayer’s Acoramidis (Beyonttra) Gets EMA Marketing Approval for ATTR-CM Treatment in EU
•
Germany-headquartered Bayer (ETR: BAYN) has received marketing approval from the European Medicines Agency (EMA) for its drug acoramidis, commercially known as Beyonttra. This near-complete (≥90%) transthyretin (TTR) stabilizer can now be used to treat wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) in the European Union (EU).…
-
Livzon Pharmaceutical’s JP-1366 Approved for Peptic Ulcer Study by NMPA
•
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has obtained approval from the National Medical Products Administration (NMPA) for its JP-1366 injection to conduct clinical studies in the treatment of peptic ulcer bleeding. This is a significant step forward for the company in the field of gastrointestinal therapeutics. About JP-1366JP-1366 is…
-
Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform
•
US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm Alloy Therapeutics Inc. The alliance is designed to develop a new platform aimed at enhancing Pfizer’s ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery…
-
Lifetech Scientific’s Aortic Stent Graft System Wins NMPA Approval
•
China-based Lifetech Scientific Corporation (HKG: 1302) announced that it has received market approval from the National Medical Products Administration (NMPA) for its aortic stent graft system, co-developed by Fuwai Hospital. Product OverviewThe aortic stent graft system is the first of its kind in China specifically designed for chimney technology. It…
